Synthesis and biological evaluation of a tumor-selective degrader of PARP1
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthesis and biological evaluation of a tumor-selective degrader of PARP1
Authors
Keywords
-
Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 69, Issue -, Pages 116908
Publisher
Elsevier BV
Online
2022-06-26
DOI
10.1016/j.bmc.2022.116908
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer
- (2022) Chunlan Pu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Repair of DNA Double-Strand Breaks by the Nonhomologous End Joining Pathway
- (2021) Benjamin M. Stinson et al. Annual Review of Biochemistry
- Discovery of a PROTAC targeting ALK with in vivo activity
- (2021) Guoyi Yan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
- (2021) Mengzhu Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
- (2021) Antti Poso JOURNAL OF MEDICINAL CHEMISTRY
- Understanding and overcoming resistance to PARP inhibitors in cancer therapy
- (2021) Mariana Paes Dias et al. Nature Reviews Clinical Oncology
- Understanding the DNA double-strand break repair and its therapeutic implications
- (2021) Ujjayinee Ray et al. DNA REPAIR
- PARP and PARG inhibitors in cancer treatment
- (2020) Dea Slade GENES & DEVELOPMENT
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
- (2020) Sajid Khan et al. ONCOGENE
- PROTAC: A promising technology for cancer treatment
- (2020) Xin Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis targeting chimeras (PROTACs) in cancer therapy
- (2020) Alberto Ocaña et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers
- (2020) Chaoguo Cao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Degradation of CDK6 by a Palbociclib Based PROTAC
- (2019) Sandeep Rana et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2019) Quanju Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
- (2019) Shuai Wang et al. Nature Chemical Biology
- Development of selective mono or dual PROTAC degrader probe of CDK isoforms
- (2019) Fei Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Overexpression of Lox in triple-negative breast cancer
- (2018) Cornelia Leo et al. Annals of Diagnostic Pathology
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- TOMAS: revisiting PARP inhibitor combination therapy
- (2018) Benjamin A Nacev et al. LANCET ONCOLOGY
- Coordination of DNA single strand break repair
- (2017) Rachel Abbotts et al. FREE RADICAL BIOLOGY AND MEDICINE
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PARP inhibitors as precision medicine for cancer treatment
- (2017) Yi Du et al. National Science Review
- Comparative PARP enzyme inhibition of PF-01367338, olaparib, and MK-4827.
- (2017) K. A. Kern et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
- (2012) Péter Bai et al. Cell Metabolism
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started